Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer

References

• SEER Stat Fact Sheets: Female Breast Cancer [Internet]. Washington (DC): National Cancer Institute. Surveillance, Epidemiology, and End Results Program; 2012. [cited 2015 Nov 1]. Available from: http://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Estimated incidence, mortality & prevalence [Internet]. Lyon: Health Organization. International Agency for Research on Cancer World; 2012. [cited 2015 Nov 1]. Available from: http://eu-cancer.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2#block-mapc-f
   Google Scholar
• Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor–positive tumors. N Engl J Med. 1989;320(8):479–484.
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2001;378(9793):771–784.
   Web of Science ®Google Scholar
• Samaan NA, Buzdar AU, Aldinger KA, et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer. 1981;47(3):554–560.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712.
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64(18):6652–6659.
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1(2):85–94.
   PubMed Web of Science ®Google Scholar
• Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatanib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzamab. Breast Cancer Res Treat. 2012;133(3):1057–1065.
   Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123(1):236–240.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
   PubMed Web of Science ®Google Scholar
• Alluri P, Newman LA. Basal-Like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am. 2014;23(3):567–577.
   PubMed Web of Science ®Google Scholar
• Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17(1):1–16.
   PubMedGoogle Scholar
• Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446–1451.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247.
   PubMed Web of Science ®Google Scholar
• Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643–658.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–726.
   PubMed Web of Science ®Google Scholar
• Easwaran H, Tsai H-C, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–727.
   PubMed Web of Science ®Google Scholar
• Vijayaraghavalu S, Dermawan JK, Cheriyath V, et al. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm. 2013;10(1):337–352.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Gallardo-Rincón D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18(9):1529–1538.
   PubMed Web of Science ®Google Scholar
• Berger SL, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–783.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726–734.
   PubMed Web of Science ®Google Scholar
• Luger K, Mader AW, Richmond RK, et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997;389(6648):251–260.
   PubMed Web of Science ®Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41–45.
   PubMed Web of Science ®Google Scholar
• Simó-Riudalbas L, Esteller M. Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol. 2015;172(11):2716–2732.
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074–1080.
   PubMed Web of Science ®Google Scholar
• You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22(1):9–20.
   PubMed Web of Science ®Google Scholar
• Dworkin AM, Huang THM, Toland AE. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19(3):165–171.
   PubMed Web of Science ®Google Scholar
• Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012;13(10):679–692.
   PubMed Web of Science ®Google Scholar
• Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol. 2004;68(6):1187–1197.
   PubMed Web of Science ®Google Scholar
• Szyf M. DNA methylation signatures for breast cancer classification and prognosis. Genome Med. 2012;4(3):26–37.
   PubMed Web of Science ®Google Scholar
• Yang X, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310–5318.
   PubMed Web of Science ®Google Scholar
• Katan-Khaykovich Y, Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev. 2002;16(6):743–752.
   PubMed Web of Science ®Google Scholar
• Verreault A, Kaufman PD, Kobayashi R, et al. Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell. 1996;87(1):95–104.
   PubMed Web of Science ®Google Scholar
• Murr R, Loizou JI, Yang YG, et al. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol. 2006;8(1):91–99.
   PubMed Web of Science ®Google Scholar
• Unnikrishnan A, Gafken PR, Tsukiyama T. Dynamic changes in histone acetylation regulate origins of DNA replication. Nat Struct Mol Biol. 2010;17(4):430–437.
   PubMed Web of Science ®Google Scholar
• Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell. 2006;23(3):289–296.
   PubMed Web of Science ®Google Scholar
• Josling GA, Selvarajah SA, Petter M, et al. The role of bromodomain proteins in regulating gene expression. Genes (Basel). 2012;3(2):320–343.
   PubMed Web of Science ®Google Scholar
• Lee JW, Lee YC, Na SY, et al. Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. Cell Mol Life Sci. 2001;58(2):289–297.
   PubMed Web of Science ®Google Scholar
• Nagy Z, Tora L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene. 2007;26(37):5341–5357.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12–27.
   PubMed Web of Science ®Google Scholar
• Di Cerbo V, Schneider R. Cancers with wrong HATs: the impact of acetylation. Brief Funct Genomics. 2013;12(3):231–243.
   PubMed Web of Science ®Google Scholar
• Wang F, Marshall C, Ikura M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol Life Sci. 2013;70(21):3989–4008.
   PubMed Web of Science ®Google Scholar
• Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000;24(3):300–303.
   PubMed Web of Science ®Google Scholar
• Xiao XS, Cai MY, Chen JW, et al. High Expression of p300 in Human Breast Cancer Correlates with Tumor Recurrence and Predicts Adverse Prognosis. Chin J Cancer Res. 2011;23(3):201–207.
   PubMed Web of Science ®Google Scholar
• Gupta A, Sharma GG, Young CSH, et al. Involvement of human MOF in ATM function. Mol Cell Biol. 2005;25(12):5292–5305.
   PubMed Web of Science ®Google Scholar
• Taipale M, Rea S, Richter K, et al. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol. 2005;25(15):6798–6810.
   PubMed Web of Science ®Google Scholar
• Kapoor-Vazirani P, Kagey JD, Powell DR, et al. Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res. 2008;68(16):6810–6821.
   PubMed Web of Science ®Google Scholar
• Pfister S, Rea S, Taipale M, et al. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 2008;122(6):1207–1213.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471(7337):235–239.
   PubMed Web of Science ®Google Scholar
• Lavau C, Du CC, Thirman M, et al. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. Embo J. 2000;19(17):4655–4664.
   PubMed Web of Science ®Google Scholar
• Marcu MG, Jung YJ, Lee S, et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem. 2006;2(2):169–174.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam K, Swaminathan V, Ranganathan A, et al. Small molecule modulators of histone acetyltransferase p300. J Biol Chem. 2003;278(21):19134–19140.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004;279(49):51163–51171.
   PubMed Web of Science ®Google Scholar
• Sen GS, Mohanty S, Hossain DMS, et al. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkappaB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem. 2011;286(49):42232–42247.
   PubMed Web of Science ®Google Scholar
• Picaud S, Fedorov O, Thanasopoulou A, et al. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Res. 2015;75(23):5106–5119.
   PubMed Web of Science ®Google Scholar
• Varier RA, Swaminathan V, Balasubramanyam K, et al. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol. 2004;68(6):1215–1220.
   PubMed Web of Science ®Google Scholar
• Zhang W, Prakash C, Sum C, et al. Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012;287(51):43137–43155.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Yik JHN, Chen RC, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535–545.
   PubMed Web of Science ®Google Scholar
• Jang MK, Mochizuki K, Zhou MS, et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523–534.
   PubMed Web of Science ®Google Scholar
• Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343–349.
   PubMed Web of Science ®Google Scholar
• Wanczyk M, Roszczenko K, Marcinkiewicz K, et al. HDACi–going through the mechanisms. Front Biosci (Landmark Ed). 2011;16:340–359.
   PubMed Web of Science ®Google Scholar
• Imai S, Armstrong CM, Kaeberlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800.
   PubMed Web of Science ®Google Scholar
• Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012;4(1):5–17.
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268–274.
   PubMed Web of Science ®Google Scholar
• Ozdag H, Teschendorff AE, Ahmed AA, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics. 2006;7(1):90–104.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 2004;10(20):6962–6968.
   PubMed Web of Science ®Google Scholar
• Valenzuela-Fernández A, Cabrero JR, Serrador JM, et al. HDAC6: a key regulator of cytoskeleton, cell migration and cell–cell interactions. Trends Cell Biol. 2008;18(6):291–297.
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–458.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. Embo J. 2003;22(5):1168–1179.
   PubMed Web of Science ®Google Scholar
• Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 2005;24(28):4531–4539.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan Z, Zhang Y, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007;27(2):197–213.
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119(11):2579–2589.
   PubMed Web of Science ®Google Scholar
• Butler KV, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc. 2010;132(31):10842–10846.
   PubMed Web of Science ®Google Scholar
• Somech R, Izraeli S, Simon JA. Histone deacetylase inhibitors–a new tool to treat cancer. Cancer Treat Rev. 2004;30(5):461–472.
   PubMed Web of Science ®Google Scholar
• Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6(3):238–243.
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000;97(18):10014–10019.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci. 2014;71(20):3885–3901.
   PubMed Web of Science ®Google Scholar
• Cimini D, Mattiuzzo M, Torosantucci L, et al. Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell. 2003;14(9):3821–3833.
   PubMed Web of Science ®Google Scholar
• Munster PN, Troso-Sandoval T, Rosen N, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001;61(23):8492–8497.
   PubMed Web of Science ®Google Scholar
• Yi X, Wei W, Wang SY, et al. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. Biochem Pharmacol. 2008;75(9):1697–1705.
   PubMed Web of Science ®Google Scholar
• Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. 2003;2(10):971–984.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Greer CB, Cecchini KR, et al. HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene. 2013;32(23):2828–2835.
   PubMed Web of Science ®Google Scholar
• Biçaku E, Marchion DC, Schmitt ML, et al. Selective inhibition of histone deacetylase 2 silences progesterone receptor–mediated signaling. Cancer Res. 2008;68(5):1513–1519.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–1428.
   PubMed Web of Science ®Google Scholar
• Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472–476.
   PubMed Web of Science ®Google Scholar
• Sarrió D, Rodriguez-Pinilla SM, Hardisson D, et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989–997.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Jones R, Liu JC, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10(10):1563–1570.
   PubMed Web of Science ®Google Scholar
• Tate CR, Rhodes LV, Segar HC, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79–R93.
   PubMed Web of Science ®Google Scholar
• Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001;61(19):7025–7029.
   PubMed Web of Science ®Google Scholar
• Fan J, Yin WJ, Lu JS, et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008;134(8):883–890.
   PubMed Web of Science ®Google Scholar
• Feng Q, Zhang Z, Shea MJ, et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014;24(7):809–819.
   PubMed Web of Science ®Google Scholar
• Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007;27(14):5105–5119.
   PubMed Web of Science ®Google Scholar
• Gonzalez ME, Li X, Toy K, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 2008;28(6):843–853.
   PubMed Web of Science ®Google Scholar
• Hodges-Gallagher L, Valentine C, Bader S, et al. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat. 2007;105(3):297–309.
   PubMed Web of Science ®Google Scholar
• Thomas S, Thurn KT, Bicaku E, et al. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011;130(2):437–447.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Ismail-Khan RR, Melichar B, et al.. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–2135.
   PubMed Web of Science ®Google Scholar
• Munster PN, Thurn KT, Thomas S, et al.. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104(12):1828–1835.
   PubMed Web of Science ®Google Scholar
• Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study. Clin Cancer Res. 2008;14(21):7138–7142.
   PubMed Web of Science ®Google Scholar
• Margueron R, Licznar A, Lazennec G, et al. Oestrogen receptor alpha increases p21 (WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol. 2003;179(1):41–53.
   PubMed Web of Science ®Google Scholar
• Fotheringham S, Epping MT, Stimson L, et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell. 2009;15(1):57–66.
   PubMed Web of Science ®Google Scholar
• Khan O, Fotheringham S, Wood V, et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A. 2010;107(14):6532–6537.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417.
   PubMed Web of Science ®Google Scholar
• Laubach JP, Moreau P, San-Miguel JF, et al. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res. 2015;21(21):4767–4773.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov: A service of the U.S National Institutes of Health [Internet]. 2015. [cited 2015 Nov 23]. Available from: https://www.clinicaltrials.gov/
   Google Scholar
• Swaby RF, Wang M, Sparano JA, et al. A phase II study of the histone deacetylase inhibitor, vorinostat, in combination with trastuzumab in patients with advanced metastatic and/or local chest wall recurrent HER-2 amplified breast cancer resistant to transtuzumab-containing therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. Cancer Res. 2009;69(24 Supplement):5084.
   Web of Science ®Google Scholar
• Stearns V, Jacobs LK, Fackler M, et al. Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer. Clin Cancer Res. 2013;19(14):4008–4016.
   PubMed Web of Science ®Google Scholar
• Connolly R, Zhao F, Miller K, et al. [OT2-01-04] E2112: randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group. SABCS. 2015.
   Google Scholar
• Leroy G, Rickards B, Flint SJ. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell. 2008;30(1):51–60.
   PubMed Web of Science ®Google Scholar
• Pivot-Pajot C, Caron C, Govin J, et al. Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol Cell Biol. 2003;23(15):5354–5365.
   PubMed Web of Science ®Google Scholar
• Shang EY, Salazar G, Crowley TE, et al. Identification of unique, differentiation stage-specific patterns of expression of the bromodomain-containing genes Brd2, Br3, Brd4, and Brdt in the mouse testis. Gene Expr Patterns. 2004;4(5):513–519.
   PubMed Web of Science ®Google Scholar
• Haynes SR, Dollard C, Winston F, et al. The bromodomain: a conserved sequence found in human, drosophila and yeast proteins. Nucleic Acids Res. 1992;20(10):2603–2603.
   PubMed Web of Science ®Google Scholar
• Hebbes TR, Thorne AW, Cranerobinson C. A direct link between core histone acetylation and transcriptionally active chromatin. Embo J. 1988;7(5):1395–1402.
   PubMed Web of Science ®Google Scholar
• Denis GV, McComb ME, Faller DV, et al. Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res. 2006;5(3):502–511.
   PubMed Web of Science ®Google Scholar
• Crowley TE, Kaine EM, Yoshida M, et al. Reproductive cycle regulation of nuclear import, euchromatic localization, and assoication with components of Pol II mediator of a mammalian double-bromodomain protein. Mol Endocrinol. 2002;16(8):1727–1737.
   PubMed Web of Science ®Google Scholar
• Sinha A, Faller DV, Denis GV. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A1. Biochem J. 2005;387(1):257–269.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Li TD, Price DH. RNA polymerase II elongation control. Annu Rev Biochem. 2012;81:119–143.
   PubMed Web of Science ®Google Scholar
• Devaiah BN, Lewis BA, Cherman N, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012;109(18):6927–6932.
   PubMed Web of Science ®Google Scholar
• French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2007;27(15):2237–2242.
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Tumang JR, Sinha A, et al. E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood. 2004;103(4):1475–1484.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073.
   PubMed Web of Science ®Google Scholar
• Berrou J, Bertrand S, Riveiro E, et al. Preclinical study of the bromodomain inhibitor OTX015 in acute myeloid (AML) and lymphoid (ALL) leukemias. Blood. 2013;122(21):4218–4218.
   Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–533.
   PubMed Web of Science ®Google Scholar
• Mirguet O, Gosmini R, Toum J, et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem. 2013;56(19):7501–7515.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917.
   PubMed Web of Science ®Google Scholar
• Chaidos A, Caputo V, Gouvedenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014;123(5):697–705.
   PubMed Web of Science ®Google Scholar
• Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308–323.
   PubMed Web of Science ®Google Scholar
• Wyce A, Ganji G, Smitheman KN, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One. 2013;8(8):e72967.
   PubMed Web of Science ®Google Scholar
• Stuhlmiller TJ, Miller SM, Zawistowski JS, et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 2015;11(3):390–404.
   PubMed Web of Science ®Google Scholar
• Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–334.
   PubMed Web of Science ®Google Scholar
• Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–947.
   PubMed Web of Science ®Google Scholar
• Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108(40):16669–16674.
   PubMed Web of Science ®Google Scholar
• Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120(14):2843–2852.
   PubMed Web of Science ®Google Scholar
• Nagarajan S, Hossan T, Alawi M, et al. Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep. 2014;8(2):459–468.
   Web of Science ®Google Scholar
• Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568–2581.
   PubMed Web of Science ®Google Scholar
• Brady-West DC, McGrowder DA. Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev. 2011;12(8):2139–2143.
   PubMedGoogle Scholar
• Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209(4):679–696.
   PubMed Web of Science ®Google Scholar
• Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232–245.
   PubMed Web of Science ®Google Scholar
• Borbely G, Haldosen LA, Dahlman-Wright K, et al. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget. 2015;6(32):33623–33635.
   PubMed Web of Science ®Google Scholar
• Shu S, Lin CY, He HH, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413–417.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang Y, Zeng L, et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell. 2014;25(2):210–225.
   PubMed Web of Science ®Google Scholar
• A dose-finding study of OTX105/MK-8628, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628-003). ClinicalTrials.gov: A service of the U.S National Institutes of Health. 2014 [cited 2015 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02259114?term=BROMODOMAIN+INHIBITORS%26rank=6
   Google Scholar
• Spannhoff A, Hauser AT, Heinke R, et al. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem. 2009;4(10):1568–1582.
   PubMed Web of Science ®Google Scholar
• Xu B, Konze KD, Jin J, et al. Targeting EZH2 and PRC2 dependence as novel anti-cancer therapy. Exp Hematol. 2015;43(8):698–712.
   PubMed Web of Science ®Google Scholar
• Caganova M, Carrisi C, Varano G, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 2013;123(12):5009–5022.
   PubMed Web of Science ®Google Scholar
• Béguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677–692.
   PubMed Web of Science ®Google Scholar
• Mochizuki-Kashio M, Mishima Y, Miyagi S, et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood. 2011;118(25):6553–6561.
   PubMed Web of Science ®Google Scholar
• Bracken AP, Dietrich N, Pasini D, et al. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20(9):1123–1136.
   PubMed Web of Science ®Google Scholar
• Laible G, Wolf A, Dorn R, et al. Mammalian homologues of the polycomb-group gene enhancer of zeste mediate gene silencing in drosophila heterochromatin and at S. cerevisiae telomeres. Embo J. 1997;16(11):3219–3232.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181–185.
   PubMed Web of Science ®Google Scholar
• Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176–181.
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–629.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Soejima K, Yasuda H, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int. 2008;8:15–26.
   PubMed Web of Science ®Google Scholar
• Ding L, Erdmann C, Chinnaiyan AM, et al. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 2006;66(8):4095–4099.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Yang JY, Xia WY, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011;19(1):86–100.
   PubMed Web of Science ®Google Scholar
• Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia. 2003;5(6):481–488.
   PubMed Web of Science ®Google Scholar
• Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J. 2003;22(20):5323–5335.
   PubMed Web of Science ®Google Scholar
• Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606–11611.
   PubMed Web of Science ®Google Scholar
• Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012;72(12):3091–3104.
   PubMed Web of Science ®Google Scholar
• Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27(58):7274–7284.
   PubMed Web of Science ®Google Scholar
• Dong C, Wu Y, Yao J, et al. G9a interacts with snail and is critical for snail-mediated E-cadherin repression in human breast cancer. J Clin Invest. 2012;122(4):1469–1486.
   PubMed Web of Science ®Google Scholar
• Cho MH, Park JH, Choi HJ, et al. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat Commun. 2015;6:7821–7834.
   PubMed Web of Science ®Google Scholar
• Li X, Gonzalez ME, Toy K, et al. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol. 2009;175(3):1246–1254.
   PubMed Web of Science ®Google Scholar
• Bhan A, Hussain I, Ansari KI, et al. Histone methyltransferase EZH2 is transcriptionally induced by estradiol as well as estrogenic endocrine disruptors bisphenol-A and diethylstilbestrol. J Mol Biol. 2014;426(20):3426–3441.
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108–112.
   PubMed Web of Science ®Google Scholar
• Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012;8(11):890–896.
   PubMed Web of Science ®Google Scholar
• Konze KD, Ma A, Li FL, et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324–1334.
   PubMed Web of Science ®Google Scholar
• Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Ohm JE. Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107–116.
   PubMed Web of Science ®Google Scholar
• Fong CY, Gilan O, Lam EY, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525(7570):538–542.
   PubMed Web of Science ®Google Scholar